From the category archives:

2005

An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor-[alpha] Antagonists

by Nick on December 1, 2005

The Impact of Age-Related Macular Degeneration on Health Status Utility Values

by Nick on November 1, 2005

A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis

by Nick on October 5, 2005

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

by Nick on July 1, 2005

The cost effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden

by Nick on July 1, 2005